Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking your Wegovy injection two days early is not recommended. Wegovy (semaglutide) is licensed as a once-weekly injection, and the seven-day interval is set deliberately — shortening it does not speed up weight loss and may increase the chance of side effects. If your schedule is temporarily disrupted, there is a short flexibility window, but two days early sits outside it. Here is what the clinical guidance actually says, and what to do instead.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy Summary of Product Characteristics (SmPC) (the authoritative clinical document published on the eMC) states that each dose should be taken once a week, on the same day each week. If a patient needs to shift their injection day, the leaflet confirms it is acceptable to take the dose up to three days earlier or three days later than scheduled, provided the next dose then follows from that new day at the usual weekly interval.
That means two days early is technically within the window the manufacturer permits as a one-off adjustment. However, there is an important distinction between using that flexibility to move your injection day permanently (for instance, switching from Monday to Saturday) and simply injecting early because the pen is to hand or because you are travelling. The first is a reasonable, prescriber-supported schedule change. The second compresses the dosing interval in a way the licence does not endorse as a regular practice.
The NHS medicines page for semaglutide is clear that Wegovy is a once-weekly injection and that you should not take an extra dose or change your schedule without speaking to a pharmacist or GP first. Worth checking that page directly if you are unsure.
Semaglutide builds up steadily in the body over several weeks of consistent dosing. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at the 2.4 mg maintenance dose alongside lifestyle changes, results achieved with a strict weekly schedule. There is no clinical evidence that taking doses early accelerates weight loss. The medicine works through sustained receptor activation; cramming doses together does not amplify that effect.
What early dosing can do is stack the side-effect profile. Nausea, diarrhoea and indigestion are most pronounced when semaglutide levels rise quickly. A shorter gap between injections means a steeper concentration curve, which is why the prescribing guidance is built around seven-day spacing. If you are already finding the current titration step difficult on the gut, reducing the interval is likely to make that harder, not easier.
There is also a practical point. Injecting two days early every week would run through your supply faster than prescribed. That can leave a gap at the end of a treatment period, disrupting the consistent rhythm that underpins the clinical results.
If you need to move your injection day (for a holiday, a medical procedure, or a shift-work pattern) the correct approach is to use the three-day flexibility window once to land on your new preferred day, then maintain that day weekly going forward. You can also find guidance on taking Wegovy a day early and on taking Wegovy three days early if your schedule shift is larger, since the principles are related.
If you are asking about taking it two days early because you are anxious about a missed dose or unsure whether you have already injected this week, that is a different situation. The general advice for a missed dose is to take it as soon as you remember, as long as the next scheduled dose is still at least two days away; if it is closer than that, skip the missed dose and carry on from the usual day. Your Patient Information Leaflet covers this precisely, and your prescriber or pharmacist can confirm the right call for your specific circumstances.
Questions about adjusting Wegovy timing more broadly are genuinely common, our prescribers hear them regularly. If anything about your dosing pattern feels uncertain, it is worth raising before your next injection rather than after. You can also explore eligibility and suitability for Wegovy if you are still in the early stages of treatment decisions, or read about the process of getting Wegovy through a regulated online pharmacy. When treatment is dispensed through a GPhC-registered pharmacy like ours, your pen arrives the next working day via DPD in plain, unmarked packaging (tracked to your door) and an Independent Prescriber is available for exactly these kinds of schedule questions through our aftercare service seven days a week.
If your question is really about the cost or structure of ongoing treatment, the treatment overview page sets out what is included. And if you would like a clinical view on your current schedule, you are welcome to speak to our prescribers at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.